Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for underserved and underrepresented populations, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

 

 

 

 

 

ECHO Grant Awarded to OUHSC

Submitted by alex on

The OCTSI has partnered with the OUHSC Department of Pediatrics and been awarded a grant from the National Institutes of Health to develop the Oklahoma Pediatric Clinical Trial Network. This network will be part of the IDeA States Pediatric Clinical Trials Network that is participating in the Environmental Impacts of Child Health Outcomes (ECHO) Program to effectively investigate the impacts of environmental exposures from the womb through later years in a child’s life. The Principal Investigator of this award is Dr. Paul Darden, Chief of General and Community Pediatrics at OUHSC.

Listening Session for AI/AN Inclusion in All of Us Program

Submitted by Anonymous (not verified) on

The Southern Plains Tribal Health Board, the Oklahoma delegation from the National Institutes of Health (NIH) Tribal Advisory Committee, and the All of Us Research Program are hosting a listening session on Tuesday, October 22, 2019 in Oklahoma City, OK.

The All of Us Research Program, part of NIH, has a simple mission: to speed up health research breakthroughs and help foster an era of precision medicine for all.

What: The goals for this listening session are to:

Subscribe to News

Recent Publications

Multi-level determinants of vaccination of the American Indian and Alaska Native population: a comprehensive overview

Front Public Health. 2025 Feb 18;13:1490286. doi: 10.3389/fpubh.2025.1490286. eCollection 2025.

ABSTRACT

CONTEXT: American Indians and Alaska Natives (AIANs) are historically disadvantaged, losing 20 million (95%) of their population largely through epidemics since 1,520 and continuing lower overall vaccination coverage than other races. Determinants of this lower coverage are underexamined.

Effect of Early and Delayed Treatment With Remdesivir on Mortality in Patients Hospitalized With COVID-19

Open Forum Infect Dis. 2025 Feb 27;12(2):ofae740. doi: 10.1093/ofid/ofae740. eCollection 2025 Feb.

ABSTRACT

BACKGROUND: We applied a target trial emulation framework to estimate the association between early and delayed initiation of remdesivir (RDV) with mortality in hospitalized adults between May 1, 2020, and July 31, 2024, with varying coronavirus disease 2019 (COVID-19) clinical severity.

Experimental induction of anti-muscarinic type-3-receptor extracellular loop antibodies by immunization with 4-hydroxy-2-nonenal modified Ro60 and unmodified Ro60

Clin Exp Immunol. 2025 Jan 21;219(1):uxae114. doi: 10.1093/cei/uxae114.

ABSTRACT

OBJECTIVE: Sjögren's Disease (SjD) subjects have decreased lacrimal/salivary gland function. Studies have proposed that autoantibodies targeting G-protein-coupled muscarinic acetylcholine-type-3-receptor (M3R) are potential clinical markers for SjD. We hypothesized that rabbits/mice immunized with 4-hydroxy-2-nonenal (HNE)-modified/unmodified Ro60 will develop an autoimmunity, specifically a SjD phenotype, thus expressing increased levels of anti-M3R antibodies.

Upcoming Events

Ethical Tribal Engagement Series

Media

Copyright © 2025 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies